Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.

ABSTRACT: Hepatocellular carcinoma (HCC) remains a global medical burden with rising incidence due to chronic viral hepatitis and non-alcoholic fatty liver diseases. Treatment of advanced disease stages is still unsatisfying. Besides first and second generation tyrosine kinase inhibitors, immune checkpoint inhibitors have become central for the treatment of HCC. New modalities like epigenetic therapy using histone deacetylase inhibitors (HDACi) and cell therapy approaches with chimeric antigen receptor T cells (CAR-T cells) are currently under investigation in clinical trials. Development of such novel drugs is closely linked to the availability and improvement of novel preclinical and animal models and the identification of predictive biomarkers. The current status of treatment options for advanced

SUBMITTER: Neureiter D 

PROVIDER: S-EPMC6626722 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature